Canada should give biopharmaceutical firms patent term extensions to recover time lost due to mandatory regulatory and marketing approvals.
Canadian policy-makers should enact legislation to define rare diseases and encourage Canadian firms to intensify their research and development of new therapies, writes Kristina Lybecker. Victor Casale photograph courtesy of Flickr
VANCOUVER, B.C. / Troy Media/ – As the old adage states, “You’ll be known by the company you keep.” As such, the implications for Canada’s biopharmaceutical sector are rather dismal.
People. Policy. Politics. This is an exclusive subscriber-only story.
'Different leadership could have decided that ‘no, we won’t collaborate with you, because we don’t have to under the legislation,’ says Parliamentary Budget Officer Yves Giroux. 'We want legislation to be clarified.'